arsenic trioxide has been researched along with febuxostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdel-Wahab, BA; El-Shoura, EAM; Shafiuddin Habeeb, M; Zafaar, D | 1 |
1 review(s) available for arsenic trioxide and febuxostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for arsenic trioxide and febuxostat
| Article | Year |
|---|---|
Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3/TLR4, Sirt-1/NF-κB/TGF-β signaling Pathways, and miR-23b-3p, miR-181a-5b expression.
Topics: Animals; Arsenic Trioxide; Febuxostat; Kidney; Kidney Diseases; MicroRNAs; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Signal Transduction; Toll-Like Receptor 4; Transforming Growth Factor beta | 2023 |